N Verses Capital, LLC Coherus Bio Sciences, Inc. Transaction History
N Verses Capital, LLC
- $167 Billion
- Q2 2024
A detailed history of N Verses Capital, LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, N Verses Capital, LLC holds 4,500 shares of CHRS stock, worth $5,850. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,500Holding current value
$5,850% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
143Shares Held
82.7MCall Options Held
79.1KPut Options Held
100K-
Black Rock Inc. New York, NY11.8MShares$15.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$13.8 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$13.5 Million0.53% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U05.82MShares$7.56 Million0.05% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$3.95 Million0.3% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $101M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...